According to new research, marijuana may be an effective therapy for patients with multiple sclerosis. While it was initially thought that the symptomatic improvements experienced by cannabinoid-administered patients with multiple sclerosis were mainly due to neurological factors, recent research discovered that cannabis substantially reduces muscle spasms and stiffness common in MS patients. Clinical studies that have been followed over the short and long term have shown the therapeutic effects of cannabis in patients with multiple sclerosis. Get more info about Holistic Releaf by Design | Medical Marijuana Dispensary in Billings MT-Dispensary Billings MT.
A team of researchers from the Peninsula Medical School in Exeter, UK, published the results of a series of short- and long-term experiments on the effects of cannabinoids in patients with multiple sclerosis in 2003. About 600 patients with advanced-stage multiple sclerosis were actively involved in previous research. Over a 15-week period, the patients were divided into two groups: the first received cannabinoid compounds in equal doses, while the second received placebo products. The majority of patients who received cannabinoids displayed significant symptomatic improvements, recorded less body pain, and had milder muscle spasticity at the end of the study (reduced severe muscle spasm). The control group (patients taking placebo medication) did not report any improvements in their clinical wellbeing compared to the cohort that received cannabinoid compounds during the study time.
The research was then repeated to confirm the relevance of the findings and to dispel some doubts about cannabinoids’ effectiveness in mitigating the symptoms of multiple sclerosis. The subsequent study was conducted over a 12-month period and included the same subjects. However, unlike the previous experiment, this time the participants were divided into three separate groups rather than two. The first party received D9-tetrahydrocannabinol (THC) pills, which are the active ingredient in cannabis, while the second received regular hemp oils and the third received a placebo.
A team of physiotherapists and neurologists carefully studied and examined the participants at the end of the study. The best results were shown in patients in the first trial group, with the majority of those who received equal doses of THC seeing significant improvements in their symptoms. Patients in the second study group indicated small improvements in their conditions, whilst those in the third group reported no improvement in their condition.